Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium, Inc. (Nasdaq: EQ) is a La Jolla, California–based clinical-stage biotechnology company that publicly describes its focus as developing novel therapies for severe autoimmune and inflammatory disorders. News about Equillium often centers on the progress of its lead candidate EQ504, an investigational aryl hydrocarbon receptor (AhR) modulator, and on corporate actions that support its development strategy.
Readers of this EQ news page can follow company announcements on clinical and preclinical plans for EQ504, including preparations for Phase 1 studies in ulcerative colitis and related gastrointestinal conditions, as well as potential applications in inflammatory lung or pulmonary diseases. Equillium’s press releases also highlight scientific and translational updates, such as key opinion leader events discussing AhR modulation, intestinal inflammation and the unmet medical need in ulcerative colitis.
In addition to pipeline news, Equillium regularly reports on financing transactions like private placements and at-the-market offerings, which it links to funding the development of EQ504 and extending its operating runway. Corporate governance and leadership updates, including changes in board composition, committee membership and senior roles, are disclosed through both SEC filings and news releases.
Another recurring topic in Equillium’s news flow is its cryptocurrency treasury reserve strategy, which the company has described as part of its broader financial and growth objectives. Updates in this area appear alongside information on cash resources, investment policy changes and strategic priorities.
Investors and observers can use this news feed to monitor Equillium’s clinical plans, scientific positioning around AhR modulation, capital-raising activities, Nasdaq listing developments and treasury strategy, all of which shape the company’s path as a clinical-stage biotech focused on immuno-inflammatory diseases.
Equillium, Inc. (Nasdaq: EQ) reports promising results from the EQUATE Phase 1b study in acute graft-versus-host disease (aGVHD), with 79% of responders maintaining complete response at six months. The study demonstrated a significant reduction in corticosteroid use among patients. The ongoing EQUATE study aims to establish itolizumab as a first-line treatment for high-risk aGVHD patients. Presentations at the 63rd Annual Meeting of ASH highlighted the drug's durability and safety profile, encouraging future clinical trials.
IMIDomics Inc. has established its Scientific and Business Advisory Boards to enhance its mission in developing precision medicines for immune-mediated inflammatory diseases (IMIDs) such as lupus and rheumatoid arthritis. The boards consist of leading experts including Dan Littman and Luisa Salter-Cid, aiding IMIDomics in leveraging its Precision Discovery Engine, which integrates extensive clinical data to innovate therapies for IMIDs. CEO Juan Harrison emphasizes the importance of advancing treatment options for these complex and often undertreated conditions.
Equillium announced plans to initiate a pivotal study of itolizumab for acute graft-versus-host disease (GVHD) after positive topline data from the EQUATE study. Interim safety data from asthma patients in the Phase 1b EQUIP study was also reported. Financially, R&D expenses increased to $7.0 million, with a net loss of $10.3 million for Q3 2021. Equillium maintains a cash balance of $90.7 million, projected to fund operations into 2023. Guidance for topline EQUIP data is set for Q4, with pivotal study commencement expected early 2022.
Equillium (Nasdaq: EQ) is set to participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 12:20 PM PT and the Jefferies Virtual London Healthcare Conference on November 18, 2021, at 12:00 AM PT. The presentations will cover the mechanism of action of itolizumab, aimed at treating severe autoimmune disorders. Leadership will conduct one-on-one meetings at both conferences. Webcast access is available on the company’s website, along with archive replays for 90 days.
Equillium, Inc. (NASDAQ: EQ) announced interim results from its Phase 1b EQUIP study evaluating itolizumab in patients with moderate to severe uncontrolled asthma. The study demonstrated that itolizumab was well tolerated, with a reduction in asthma control questionnaire scores from 2.5 to 1.5 at Day 29. The mean FEV-1 improved from 2.1 to 2.4 by Day 29, maintaining this improvement at Day 85. Adverse events were mainly mild to moderate. Topline data is expected later this year, highlighting itolizumab's potential in treating severe asthma.
Equillium (NASDAQ: EQ) released positive interim data from the Phase 1b EQUALISE study of its drug itolizumab for patients with systemic lupus erythematosus (SLE). Results showed up to a 53% decrease in proteinuria, indicating potential kidney protection. The treatment was well tolerated, with mild to moderate side effects reported. Pharmacodynamic data revealed dose-dependent reductions in the inflammatory marker CD6. These findings support the drug's mechanism targeting the CD6-ALCAM pathway and highlight the ongoing research into its efficacy for SLE and lupus nephritis.
Equillium, Inc. (Nasdaq: EQ) has announced the acceptance of two abstracts for presentation at the American Society of Hematology's 63rd annual meeting, taking place from December 11-14, 2021. The presentations will focus on Itolizumab, a novel targeted therapy for acute graft-versus-host disease (GVHD). Dr. John Koreth from Dana Farber will present one abstract on the drug's efficacy in treating newly diagnosed acute GVHD, while another, led by Equillium's Dalena Chu, discusses CD6 antigenic modulation. Both abstracts will also be published in Blood's November supplemental issue.
Equillium announced promising interim data from the EQUALISE study on itolizumab for systemic lupus erythematosus (SLE). Notably, patients showed a reduction of 42% in proteinuria and 54% in albuminuria after treatment. The study involved 35 SLE patients and confirmed that itolizumab was well tolerated at doses from 0.4 to 2.4 mg/kg. Findings suggest it could be effective in treating SLE and related complications, with further data expected from ongoing research.
Equillium, Inc. (Nasdaq: EQ) has announced the acceptance of two abstracts for presentation at the virtual 2021 American Society of Nephrology Annual Meeting, taking place from November 4-7, 2021. The abstracts focus on itolizumab, a novel anti-CD6 antibody, and highlight its safety and efficacy in treating systemic lupus erythematosus (SLE). The EQUALISE study evaluates itolizumab's effects on patients with SLE and lupus nephritis. Itolizumab is designed to modulate immune responses in severe autoimmune disorders.
Equillium, Inc. (Nasdaq: EQ) has announced that three abstracts will be presented at the ACR Convergence from November 3-10, highlighting the use of itolizumab for treating systemic lupus erythematosus (SLE) and lupus nephritis. The abstracts report on safety results from the Phase 1b EQUALISE study, pharmacodynamic markers, and the potential role of urinary ALCAM as a biomarker for renal disease activity. Itolizumab is a first-in-class monoclonal antibody targeting the CD6-ALCAM pathway, aimed at managing severe autoimmune disorders.